ARTHUR-D.-LITTLE
Whatever the success of climate change mitigation measures, companies and society will need to adapt to a changing world. To aid business climate change adaptation strategies, Arthur D. Little (ADL)’s Blue Shift Institute today published We’re doomed, now what?, an in-depth report that sets out five potential scenarios for adaptation and highlights relevant technologies to focus on.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240627698200/en/
Arthur D. Little Blue Shift Institute Report Outlines 5 Scenarios for Future of Climate Change Adaptation (Graphic: Business Wire)
The report is based on extensive analysis, interviews with over 40 international experts, surveys of business leaders, and was created in close collaboration with the United Nation’s (UN’s) World Intellectual Property Organization (WIPO).
It works on a “+3°C by 2100” outcome for climate change, based on projections by the Intergovernmental Panel on Climate Change (IPCC) and uses this to underpin five potential, non-exclusive scenarios for the future of climate change adaptation:
- Green Communities: A resource-scarce world in which grassroots initiatives flourish, for lack of more ambitious projects; there is a pull towards greater decentralization, circularity, and frugality
- Lonely at the top: Highly concentrated and competitive industries in which market leaders spearhead adaptation to build competitive advantage and keep satisfying consumers, while operating under increasing constraints
- Wild Green West: A creative chaos in which private adaptation initiatives sprout everywhere, fueled by private capital and hype, with no overarching strategy or consistency
- Don’t Look Up: A bleak future in which neither customers nor finance institutions have adjusted to the new climate reality, leaving nothing but quick fixes and crisis management
- Adaptation Surge: A world in which adaptation is the norm and the new currency, resetting expectations, creating new markets and new needs for differentiation, and possibly overengineering
For each of these futures the report outlines the functional expectations and relevant technologies to drive adaptation. Alongside this, it includes “no regret” solutions, enabling technologies, and capabilities that will be vital, whatever the future brings, and that companies should invest in now.
Dr. Albert Meige, Global Director of Blue Shift at Arthur D. Little, comments: “When faced with prospective technology choices, executives often need to address three challenges: complexity, speed and cognition. Adaptation to climate change is no different. It is complex because climate impacts are local, multifactorial and highly variable; and also because there is a myriad of adaptation technologies available. By modeling potential scenarios we aim to cut through this complexity, providing CEOs with a clear guide to the potential technologies that their adaptation will require.”
Dr. Peter Oksen, Senior Program Officer at the World Intellectual Property Organization (WIPO) GREEN, comments: “This report offers a refreshing new angle to climate action, namely that of businesses and their priorities for adapting to a challenging future. It provides the scenario-based context for the technologies outlined by WIPO GREEN, underscoring the essential role of innovation in forging a sustainable future. By detailing the functional expectations and key technologies necessary for adaptation, it highlights the need to integrate technological advancements within our business, economic and policy frameworks to effectively combat climate change.”
We’re doomed, now what? can be accessed here: https://tinyurl.com/4w35xahm
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627698200/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
